Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching.
Mack
George S
GS
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D058846:Antibodies, Monoclonal, Murine-Derived; D001709:Biotechnology / Q000331:legislation & jurisprudence; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D000068579:Celecoxib; D003486:Cyanides / Q000494:pharmacology; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D000068800:Etanercept; D006146:Guanidines / Q000494:pharmacology; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D053590:Interleukin 1 Receptor Antagonist Protein; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D011486:Protein C / Q000494:pharmacology; D011719:Pyrazines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D020849:Raloxifene Hydrochloride / Q000494:pharmacology; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins / Q000494:pharmacology; D000069283:Rituximab; D012795:Sialoglycoproteins / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology; D014481:United States
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; D003486:Cyanides; D006146:Guanidines; C507763:IL1RN protein, human; D007074:Immunoglobulin G; D053590:Interleukin 1 Receptor Antagonist Protein; C401312:N-(6-chlorophenoxyhexyl)-N''-cyano-N''-4-pyridylguanidine; D016328:NF-kappa B; D011486:Protein C; D011719:Pyrazines; D011720:Pyrazoles; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; D013449:Sulfonamides; D000069283:Rituximab; D020849:Raloxifene Hydrochloride; D000069286:Bortezomib; D000068579:Celecoxib; C421124:drotrecogin alfa activated; D000068800:Etanercept